APOC1 and Hyperglycemia: Moreover, the lack of difference in apoC1 isoforms in mass spectrometry between uncontrolled T1D patients at baseline and improved glycemic control at 3 months reinforces the idea that hyperglycemia, via glycation, does not play a major role in vivo in the loss of function observed in T1D.